Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Jubilant, Wistar Institute to Evaluate Novel PAD4 Inhibitors to Reduce Severity of COVID-19

americanpharmaceuticalreviewJanuary 25, 2021

Tag: Jubilant , Wistar Institute , COVID-19 , PAD4

PharmaSources Customer Service